An observational study in COPD, sponsored by Initiatives Bronchopneumopathie Chronique Obstructive (BPCO). Recruiting at 7 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Initiatives Bronchopneumopathie Chronique Obstructive (BPCO) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France — 71 open to participants now, 81 under way, 10 of them phase 3. Pulmonary Disease, Chronic Obstructive · France.
Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, this one is the 17th largest by planned enrollment of the 119 observational ones that give a count, is one of 20 that started in 2026, is one of 119 observational ones, reaches primary completion later than 74 of the 80 other live ones, and was the 395th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →71 of the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France are open now. Recruiting first, the newest first:
Fondation Hôpital Saint-Joseph · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
Eli Lilly and Company · Sites in France, United States, Argentina and 15 more countries
Ages 40–75
CHU de Reims · Sites in France
Ages 18+
Groupe Hospitalier du Havre · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
406 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 24 · Phase 3 84 · Phase 4 20
First in 2000; this study’s year is marked. 20 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 159 across 1,498 observational studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 138 across the 286 interventional studies, 100 across the 119 observational. Of the 299 that completed or were terminated, 70 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
136 of 406 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Initiatives Bronchopneumopathie Chronique Obstructive (BPCO) as lead sponsor.
Initiatives Bronchopneumopathie Chronique Obstructive (BPCO) has 1 study filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
16 of the studies in Pulmonary Disease, Chronic Obstructive with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT05844462Phase 3Assistance Publique - Hôpitaux de ParisTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease | 2027-10 |
| NCT07125989Centre Hospitalier Universitaire de Saint EtienneEffect of Exercise Ventilatory Support Pressure on Endurance in Patients With Severe Chronic Obstructive Pulmonary Disease - AVE-BPCO | 2027-01 |
| NCT04339270University Hospital, MontpellierChronic Airway Disease, Mucus Rheology and Exacerbations | 2027-02 |
| NCT06653933University Hospital, GrenobleStudy of Sleep Quality in the Intensive Care Unit and Association with Weaning from Invasive Ventilation in Patients with Chronic Obstructive Bronchopneumopathy. | 2027-02-01 |
Add all 16 to your calendar (.ics) → With an account.
Among the 406 studies in Pulmonary Disease, Chronic Obstructive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, multicenter, real-world observational cohort study will describe phenotypic profiles, patient characteristics, and treatments in adults with stable chronic obstructive pulmonary disease (COPD). The profiles observed in the current cohort will be compared with those of patients recruited between 2005 and 2018 in the previous COPD-BPCO 1 cohort. Patients will be followed for at least 3 years as part of routine care, with no study-specific visit or treatment.
COPD is a heterogeneous disease, and patient characteristics may be associated with prognosis and treatment response. The previous Initiative BPCO cohort recruited 1,720 subjects between 2005 and 2018 and identified clinically relevant COPD phenotypes, including subgroups associated with mortality risk. Because diagnostic strategies, risk factors, comorbidity management, and COPD treatments have evolved, this new prospective dynamic cohort will assess whether current COPD phenotypes differ from those previously identified and whether classification and regression tree (CART) algorithms developed in the previous cohort remain applicable. Data will be collected during routine care from hospital pulmonology centers in France. Baseline and follow-up data may include demographics, risk factors, comorbidities, usual treatments, patient-reported questionnaires, pulmonary function, arterial blood gases, 6-minute walk test, imaging, biology results, exacerbations, and mortality status.
Adult patients with stable COPD followed in French hospital pulmonology centers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 18 years or older.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults with stable COPD confirmed by post-bronchodilator FEV1/FVC \< 70%, recruited during routine pulmonology care
Other: Routine care / no study-specific intervention
Patients will be managed according to usual care at the investigator's discretion. The study does not assign any treatment, medicinal product, or medical device.
Identification and description of COPD phenotypic profiles
COPD phenotypic subgroups will be defined using unsupervised clustering and described according to patient characteristics, treatments, pulmonary function, symptoms, exacerbations, clinically important deterioration, and mortality
Time frame: Baseline and up to 3 years
Comparison of phenotypic profiles with the previous COPD-BPCO 1 cohort
Baseline and up to 3 years
Time frame: Current profiles will be compared with those observed in the previous cohort recruited between 2005 and 2018.
Prognosis of current patients compared with the previous cohort
Prognosis will be explored using mortality at 3 years, exacerbations, pulmonary function, dyspnea, health status, treatment modifications, and clinically important deterioration
Time frame: 3 years
Applicability of previously developed CART algorithms
Classification and regression tree algorithms developed from COPD-BPCO 1 will be applied to the new cohort and, if needed, new classification trees will be developed.
Time frame: Through study completion, an average of 3 years
Adverse events
Number and detailed description of adverse events collected as part of the study, although no adverse event related to the study itself is expected.
Time frame: Through study completion, an average of 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.
Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 43 months is above that.
Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →